Sari Rasheed
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sari Rasheed has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Rolf Müller
Saarland University
7 shared publications - Alexander Titz
Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research, Saarbrücken, D-66123, Germany; Deutsches Zentrum für Infektionsforschung (DZIF), Standort Hannover-Braunschweig, Germany; Department of Chemistry, PharmaScienceHub (PSH), Saarland University, Saarbrücken, D-66123, Germany
2 shared publications - Bassam El Hafi
Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth
2 shared publications - George Farah Araj
Department of Pathology and Laboratory Medicine, American University of Beirut Medical Center, Beirut 1107 2020, Lebanon
2 shared publications - Ghassan M. Matar
Department of Experimental Pathology, Immunology, and Microbiology, Faculty of Medicine, American University of Beirut, Beirut, Lebanon
2 shared publications - Jan Dastbaz
Deutsches Zentrum für Infektionsforschung (DZIF) Standort Hannover-Braunschweig 38124 Braunschweig Germany
2 shared publications
Latest Publications
- Open Access
- 17 October 2026
- Published by Springer Nature in Communications Chemistry
- Vol. 9 (1) , 327
Targeted pathway mining reveals novel modified hexapeptides from the demiguisin family
Following the discovery of the piperazic acid (Piz)-containing hexapeptide demiguisin A from a toxic bird-associated Amycolatopsis strain, we aimed to investigate the structural diversity and bioactive potential of this natural product family. Here, we used the dmg biosynthetic gene cluster from Amycolatopsis sp. PS_44_ISF1 as a pathway mining probe to search for alternative demiguisin A producers. A global search identified only one other soil-derived Amycolatopsis sp. NBC_01488, encoding a highly syntenic pathway. Under feather-mimicking conditions, PS_44_ISF1 demonstrated enhanced growth and metabolite production relative to NBC_01488. Despite phylogenomic distance, both strains produced shared metabolites, while NBC_01488 yielded more abundant demiguisins, enabling the isolation of five novel derivatives characterized by two Piz-moieties with different hydroxylation patterns and glycine truncation. Two congeners displayed potent activity against the avian pathogen Mycobacterium intracellulare and moderate activity against Mycobacterium tuberculosis . These findings show that targeted pathway mining guided the expansion of the chemical diversity of Piz-modifications and demiguisin congeners with promising anti- Mycobacterium activity.
- 17 October 2026
- Published by Springer Nature in Communications Chemistry
- Vol. 9 (1) , 327
Open AccessTargeted pathway mining reveals novel modified hexapeptides from the demiguisin family
Following the discovery of the piperazic acid (Piz)-containing hexapeptide demiguisin A from a toxic bird-associated Amycolatopsis strain, we aimed to investigate the structural diversity and bioactive potential of this natural product family. Here, we used the dmg biosynthetic gene cluster from Amycolatopsis sp. PS_44_ISF1 as a pathway mining probe to search for alternative demiguisin A producers. A global search identified only one other soil-derived Amycolatopsis sp. NBC_01488, encoding a highly syntenic pathway. Under feather-mimicking conditions, PS_44_ISF1 demonstrated enhanced growth and metabolite production relative to NBC_01488. Despite phylogenomic distance, both strains produced shared metabolites, while NBC_01488 yielded more abundant demiguisins, enabling the isolation of five novel derivatives characterized by two Piz-moieties with different hydroxylation patterns and glycine truncation. Two congeners displayed potent activity against the avian pathogen Mycobacterium intracellulare and moderate activity against Mycobacterium tuberculosis . These findings show that targeted pathway mining guided the expansion of the chemical diversity of Piz-modifications and demiguisin congeners with promising anti- Mycobacterium activity.
- Open Access
TopFor: Automated Preparation of AMBER-Compatible Parameters for Noncanonical Amino Acids in Peptides
Peptides containing noncanonical amino acids (ncAAs) are becoming increasingly important in drug discovery, but their molecular dynamics (MD) simulation remains limited by labor-intensive residue parameterization and topology preparation. Here, we present TopFor (Topology and Residue Force-Field Parameter Preparation), an open-source, peptide-oriented workflow that automates the generation of ncAA residue templates and force-field parameter files for MD simulations with AMBER using established charge-derivation methods. TopFor supports single-residue, whole-peptide, and batch parameterization workflows. The workflow was validated using the MDM2–p53 complex by comparing native AMBER residue definitions with residues processed by TopFor using three charge-derivation methods, each evaluated in three independent 100 ns MD simulations. TopFor-generated residue definitions showed structural and conformational behavior comparable to the native AMBER representation. Applicability to more complex peptide architectures was demonstrated using the head-to-tail cyclic peptide cyclosporin A and the cyclic depsipeptide cyclohexylgriselimycin. At library scale, 1,138 of 1,214 cyclohexylgriselimycin derivatives (93.7%) successfully completed TopFor parameterization and the subsequent initial AMBER-based computational workflow across two derivatization campaigns. TopFor was further integrated into a structure-based peptide discovery workflow based on the DnaN–griselimycin complex. Six GM-derived peptides were computationally prioritized and experimentally evaluated, of which four produced SPR responses against Mycobacterium smegmatis (M. smegmatis) DnaN and three showed concentration-dependent responses. TopFor reduces the manual effort required to prepare ncAA-containing peptides for MD simulations and enables their integration into both library-scale computational screening and structure-based peptide discovery workflows.
Open AccessTopFor: Automated Preparation of AMBER-Compatible Parameters for Noncanonical Amino Acids in Peptides
Peptides containing noncanonical amino acids (ncAAs) are becoming increasingly important in drug discovery, but their molecular dynamics (MD) simulation remains limited by labor-intensive residue parameterization and topology preparation. Here, we present TopFor (Topology and Residue Force-Field Parameter Preparation), an open-source, peptide-oriented workflow that automates the generation of ncAA residue templates and force-field parameter files for MD simulations with AMBER using established charge-derivation methods. TopFor supports single-residue, whole-peptide, and batch parameterization workflows. The workflow was validated using the MDM2–p53 complex by comparing native AMBER residue definitions with residues processed by TopFor using three charge-derivation methods, each evaluated in three independent 100 ns MD simulations. TopFor-generated residue definitions showed structural and conformational behavior comparable to the native AMBER representation. Applicability to more complex peptide architectures was demonstrated using the head-to-tail cyclic peptide cyclosporin A and the cyclic depsipeptide cyclohexylgriselimycin. At library scale, 1,138 of 1,214 cyclohexylgriselimycin derivatives (93.7%) successfully completed TopFor parameterization and the subsequent initial AMBER-based computational workflow across two derivatization campaigns. TopFor was further integrated into a structure-based peptide discovery workflow based on the DnaN–griselimycin complex. Six GM-derived peptides were computationally prioritized and experimentally evaluated, of which four produced SPR responses against Mycobacterium smegmatis (M. smegmatis) DnaN and three showed concentration-dependent responses. TopFor reduces the manual effort required to prepare ncAA-containing peptides for MD simulations and enables their integration into both library-scale computational screening and structure-based peptide discovery workflows.
- Open Access
- 7 April 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (4) , e0359025
Evaluation of commercial susceptibility testing methods for in vitro determining daptomycin susceptibility in vancomycin-resistant Enterococcus faecium
Vancomycin-resistant Enterococcus faecium (VR Efm ) is a major cause of invasive healthcare-associated infections. Daptomycin is an important treatment option, but its efficacy may be compromised for isolates with minimum inhibitory concentrations (MICs) of 4–8 mg/L, even at high doses. EUCAST has therefore assigned an “insufficient evidence” category for Enterococcus spp., making accurate MIC determination essential. We compared the performance of UMIC Daptomycin, several automated broth microdilution (BMD) systems, and E-test against the reference BMD method. Eighty-nine VR Efm isolates with borderline daptomycin susceptibility were tested by standard BMD in calcium-adjusted Mueller–Hinton broth and by Phoenix, EUVENC, VITEK-2, UMIC Daptomycin, and E-test. CLSI breakpoints (susceptible-dose dependent ≤ 4 mg/L, R > 4 mg/L) were applied. Essential agreement (EA), categorical agreement (CA), bias, very major errors (vMEs), and major errors were assessed. Phoenix (EA = 92%, CA = 69%) and EUVENC (EA = 87.6%, CA = 74.2%) were the most accurate. UMIC achieved EA = 74.2% and CA = 70.8%. E-test (EA = 68.5%, CA = 66.3%) and VITEK-2 (EA = 67.4%, CA = 64%) showed lower accuracy. All methods displayed negative bias, underestimating MICs and frequently misclassifying isolates with MIC = 8 mg/L, resulting in high vME rates. None of the methods met ISO-20776-2:2021 criteria. Automated BMD systems performed best, but all showed systematic MIC underestimation near the breakpoint. For reliable detection and confirmation of daptomycin resistance in VR Efm , BMD-based MIC methods—manual or automated—are recommended. IMPORTANCE: Vancomycin-resistant Enterococcus faecium (VR Efm ) is a major cause of hospital-acquired infections worldwide, posing a serious threat to patient safety and infection control. Daptomycin remains one of the few therapeutic options for severe VR Efm infections, yet its efficacy depends on accurately determining bacterial susceptibility. Even small variations in measured minimum inhibitory concentrations can influence treatment success or failure. In this study, we systematically evaluated several commercial antimicrobial susceptibility testing methods for daptomycin against VR Efm and compared them with the reference broth microdilution (BMD) method. Our results show that many commonly used systems underestimate resistance, particularly for isolates near the clinical breakpoint. This underestimation may lead to inappropriate treatment decisions. The study provides evidence-based recommendations for clinical laboratories and emphasizes the importance of confirmatory BMD testing to ensure reliable results, optimize patient management, and prevent the further spread of antimicrobial resistance.
- 7 April 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (4) , e0359025
Open AccessEvaluation of commercial susceptibility testing methods for in vitro determining daptomycin susceptibility in vancomycin-resistant Enterococcus faecium
Vancomycin-resistant Enterococcus faecium (VR Efm ) is a major cause of invasive healthcare-associated infections. Daptomycin is an important treatment option, but its efficacy may be compromised for isolates with minimum inhibitory concentrations (MICs) of 4–8 mg/L, even at high doses. EUCAST has therefore assigned an “insufficient evidence” category for Enterococcus spp., making accurate MIC determination essential. We compared the performance of UMIC Daptomycin, several automated broth microdilution (BMD) systems, and E-test against the reference BMD method. Eighty-nine VR Efm isolates with borderline daptomycin susceptibility were tested by standard BMD in calcium-adjusted Mueller–Hinton broth and by Phoenix, EUVENC, VITEK-2, UMIC Daptomycin, and E-test. CLSI breakpoints (susceptible-dose dependent ≤ 4 mg/L, R > 4 mg/L) were applied. Essential agreement (EA), categorical agreement (CA), bias, very major errors (vMEs), and major errors were assessed. Phoenix (EA = 92%, CA = 69%) and EUVENC (EA = 87.6%, CA = 74.2%) were the most accurate. UMIC achieved EA = 74.2% and CA = 70.8%. E-test (EA = 68.5%, CA = 66.3%) and VITEK-2 (EA = 67.4%, CA = 64%) showed lower accuracy. All methods displayed negative bias, underestimating MICs and frequently misclassifying isolates with MIC = 8 mg/L, resulting in high vME rates. None of the methods met ISO-20776-2:2021 criteria. Automated BMD systems performed best, but all showed systematic MIC underestimation near the breakpoint. For reliable detection and confirmation of daptomycin resistance in VR Efm , BMD-based MIC methods—manual or automated—are recommended. IMPORTANCE: Vancomycin-resistant Enterococcus faecium (VR Efm ) is a major cause of hospital-acquired infections worldwide, posing a serious threat to patient safety and infection control. Daptomycin remains one of the few therapeutic options for severe VR Efm infections, yet its efficacy depends on accurately determining bacterial susceptibility. Even small variations in measured minimum inhibitory concentrations can influence treatment success or failure. In this study, we systematically evaluated several commercial antimicrobial susceptibility testing methods for daptomycin against VR Efm and compared them with the reference broth microdilution (BMD) method. Our results show that many commonly used systems underestimate resistance, particularly for isolates near the clinical breakpoint. This underestimation may lead to inappropriate treatment decisions. The study provides evidence-based recommendations for clinical laboratories and emphasizes the importance of confirmatory BMD testing to ensure reliable results, optimize patient management, and prevent the further spread of antimicrobial resistance.
- Open Access
Adaptations of gram-negative and gram-positive probiotic bacteria in engineered living materials
Encapsulation of microbes in natural or synthetic matrices is a key aspect of engineered living materials, although the influence of such confinement on microbial behavior is poorly understood. A few recent studies have shown that spatial confinement and mechanical properties of the encapsulating material significantly influence microbial behavior, including growth, metabolism, and gene expression. While such effects have been shown to elicit various responses in a few micro-organisms like E. coli , yeast, and cyanobacteria, systematic comparative studies between different organisms in the same confinement conditions are missing. Thus, in this study, we report the adaptive responses exhibited by rod-shaped gram-negative and gram-positive probiotic bacteria that are of great interest for developing therapeutic engineered living materials. Accordingly, gram-negative E. coli Nissle 1917 and gram-positive L. plantarum WCFS1 were encapsulated in hydrogel matrices and their growth, metabolic activity, and recombinant gene expression were investigated. By varying the polymer concentration and degree of chemical cross-linking in the hydrogels, it was possible to modulate their stiffness and study how the bacteria adapted to these different confinement conditions. In accordance with previous reports, both bacteria grow from single cells into confined colonies but more interestingly, in E. coli gels, mechanical properties influenced colony growth, size, and morphology, whereas this did not occur in L. plantarum gels. However, with both bacteria, increased matrix stiffness led to higher levels of recombinant protein production within the colonies. By measuring metabolic heat generated in the bacterial gels using a novel isothermal microcalorimetry technique, it was inferred that E. coli adapts to the mechanical restrictions through multiple metabolic transitions and is significantly affected by the different hydrogel properties. Contrastingly, both these aspects were not observed with L. plantarum . These results revealed that despite both these bacteria being gut-adapted probiotics with similar geometries, mechanical confinement affects them considerably differently. The weaker influence of matrix stiffness on L. plantarum is attributed to its slower growth and thicker cell wall possibly enabling the generation of higher turgor pressures to overcome restrictive forces under confinement. By providing fundamental insights into the interplay between mechanical forces and bacterial physiology, this work advances our understanding of how matrix properties shape bacterial behavior. The implications of these findings will aid the design of engineered living materials for therapeutic applications.
Open AccessAdaptations of gram-negative and gram-positive probiotic bacteria in engineered living materials
Encapsulation of microbes in natural or synthetic matrices is a key aspect of engineered living materials, although the influence of such confinement on microbial behavior is poorly understood. A few recent studies have shown that spatial confinement and mechanical properties of the encapsulating material significantly influence microbial behavior, including growth, metabolism, and gene expression. While such effects have been shown to elicit various responses in a few micro-organisms like E. coli , yeast, and cyanobacteria, systematic comparative studies between different organisms in the same confinement conditions are missing. Thus, in this study, we report the adaptive responses exhibited by rod-shaped gram-negative and gram-positive probiotic bacteria that are of great interest for developing therapeutic engineered living materials. Accordingly, gram-negative E. coli Nissle 1917 and gram-positive L. plantarum WCFS1 were encapsulated in hydrogel matrices and their growth, metabolic activity, and recombinant gene expression were investigated. By varying the polymer concentration and degree of chemical cross-linking in the hydrogels, it was possible to modulate their stiffness and study how the bacteria adapted to these different confinement conditions. In accordance with previous reports, both bacteria grow from single cells into confined colonies but more interestingly, in E. coli gels, mechanical properties influenced colony growth, size, and morphology, whereas this did not occur in L. plantarum gels. However, with both bacteria, increased matrix stiffness led to higher levels of recombinant protein production within the colonies. By measuring metabolic heat generated in the bacterial gels using a novel isothermal microcalorimetry technique, it was inferred that E. coli adapts to the mechanical restrictions through multiple metabolic transitions and is significantly affected by the different hydrogel properties. Contrastingly, both these aspects were not observed with L. plantarum . These results revealed that despite both these bacteria being gut-adapted probiotics with similar geometries, mechanical confinement affects them considerably differently. The weaker influence of matrix stiffness on L. plantarum is attributed to its slower growth and thicker cell wall possibly enabling the generation of higher turgor pressures to overcome restrictive forces under confinement. By providing fundamental insights into the interplay between mechanical forces and bacterial physiology, this work advances our understanding of how matrix properties shape bacterial behavior. The implications of these findings will aid the design of engineered living materials for therapeutic applications.
- Open Access
- 23 December 2022
- Published by Wiley in ChemBioChem
- Vol. 24 (3)
Pineapple Lectin AcmJRL Binds SARS‐CoV‐2 Spike Protein in a Carbohydrate‐Dependent Fashion**
The highly glycosylated spike protein of SARS‐CoV‐2 is essential for infection and constitutes a prime target for antiviral agents and vaccines. The pineapple‐derived jacalin‐related lectin AcmJRL is present in the medication bromelain in significant quantities and has previously been described to bind mannosides. Here, we performed a large ligand screening of AcmJRL by glycan array analysis, quantified the interaction with carbohydrates and validated high‐mannose glycans as preferred ligands. Because the SARS‐CoV‐2 spike protein was previously reported to carry a high proportion of high‐mannose N‐glycans, we tested the binding of AcmJRL to the recombinantly produced extraviral domain of spike protein. We could demonstrate that AcmJRL binds the spike protein with a low‐micromolar KD in a carbohydrate‐dependent fashion.
- 23 December 2022
- Published by Wiley in ChemBioChem
- Vol. 24 (3)
Open AccessPineapple Lectin AcmJRL Binds SARS‐CoV‐2 Spike Protein in a Carbohydrate‐Dependent Fashion**
The highly glycosylated spike protein of SARS‐CoV‐2 is essential for infection and constitutes a prime target for antiviral agents and vaccines. The pineapple‐derived jacalin‐related lectin AcmJRL is present in the medication bromelain in significant quantities and has previously been described to bind mannosides. Here, we performed a large ligand screening of AcmJRL by glycan array analysis, quantified the interaction with carbohydrates and validated high‐mannose glycans as preferred ligands. Because the SARS‐CoV‐2 spike protein was previously reported to carry a high proportion of high‐mannose N‐glycans, we tested the binding of AcmJRL to the recombinantly produced extraviral domain of spike protein. We could demonstrate that AcmJRL binds the spike protein with a low‐micromolar KD in a carbohydrate‐dependent fashion.
- 19 December 2022
- Published by Elsevier in Journal of Controlled Release
- Vol. 353, 915-929
Proteoid biodynamers for safe mRNA transfection via pH-responsive nanorods enabling endosomal escape
- 19 December 2022
- Published by Elsevier in Journal of Controlled Release
- Vol. 353, 915-929
Proteoid biodynamers for safe mRNA transfection via pH-responsive nanorods enabling endosomal escape
- Open Access
The Glycan-Specificity of the Pineapple Lectin AcmJRL and its Carbohydrate-Dependent Binding of the SARS-CoV-2 Spike Protein
The current SARS-CoV-2 pandemic has become one of the most challenging global health threats, with over 530 million reported infections by May 2022. In addition to vaccines, research and development have also been directed towards novel drugs. Since the highly glycosylated spike protein of SARS-CoV-2 is essential for infection, it constitutes a prime target for antiviral agents. The pineapple-derived jacalin-related lectin (AcmJRL) is present in the medication bromelain in significant quantities and has previously been described to bind mannosides. Here, we elucidated its ligand specificity by glycan array analysis, quantified the interaction with carbohydrates and validated high-mannose glycans as preferred ligands. Because the SARS-CoV-2 spike protein was previously reported to carry a high proportion of high-mannose N-glycans, we tested the binding of AcmJRL to recombinantly produced spike protein. We could demonstrate that AcmJRL binds the spike protein with a low micromolar K D in a carbohydrate-dependent fashion, suggesting its use as a potential SARS-CoV-2 neutralising agent.
Open AccessThe Glycan-Specificity of the Pineapple Lectin AcmJRL and its Carbohydrate-Dependent Binding of the SARS-CoV-2 Spike Protein
The current SARS-CoV-2 pandemic has become one of the most challenging global health threats, with over 530 million reported infections by May 2022. In addition to vaccines, research and development have also been directed towards novel drugs. Since the highly glycosylated spike protein of SARS-CoV-2 is essential for infection, it constitutes a prime target for antiviral agents. The pineapple-derived jacalin-related lectin (AcmJRL) is present in the medication bromelain in significant quantities and has previously been described to bind mannosides. Here, we elucidated its ligand specificity by glycan array analysis, quantified the interaction with carbohydrates and validated high-mannose glycans as preferred ligands. Because the SARS-CoV-2 spike protein was previously reported to carry a high proportion of high-mannose N-glycans, we tested the binding of AcmJRL to recombinantly produced spike protein. We could demonstrate that AcmJRL binds the spike protein with a low micromolar K D in a carbohydrate-dependent fashion, suggesting its use as a potential SARS-CoV-2 neutralising agent.
- Open Access
- 30 April 2019
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 10, 933
Evaluating the Efficacies of Carbapenem/β-Lactamase Inhibitors Against Carbapenem-Resistant Gram-Negative Bacteria in vitro and in vivo
Background: Carbapenem-resistant Gram-negative bacteria are a major clinical concern as they cause virtually untreatable infections since carbapenems are among the last-resort antimicrobial agents. β-Lactamases implicated in carbapenem resistance include KPC, NDM, and OXA-type carbapenemases. Antimicrobial combination therapy is the current treatment approach against carbapenem resistance in order to limit the excessive use of colistin; however, its advantages over monotherapy remain debatable. An alternative treatment strategy would be the use of carbapenem/β-lactamase inhibitor (βLI) combinations. In this study, we assessed the in vitro and in vivo phenotypic and molecular efficacies of three βLIs when combined with different carbapenems against carbapenem-resistant Gram-negative clinical isolates. The chosen βLIs were (1) Avibactam, against OXA-type carbapenemases, (2) calcium-EDTA, against NDM-1, and (3) Relebactam, against KPC-2. Methods: Six Acinetobacter baumannii clinical isolates were screened for blaOXA-23-like, blaOXA-24/40, blaOXA-51-like, blaOXA-58, and blaOXA-143-like, and eight Enterobacteriaceae clinical isolates were screened for blaOXA-48, blaNDM-1, and blaKPC-2. The minimal inhibitory concentrations of Imipenem (IPM), Ertapenem (ETP), and Meropenem (MEM) with corresponding βLIs for each isolate were determined. The efficacy of the most suitable in vitro treatment option against each of blaOXA-48, blaNDM-1, and blaKPC-2 was assessed via survival studies in a BALB/c murine infection model. Finally, RT-qPCR was performed to assess the molecular response of the genes of resistance to the carbapenem/βLI combinations used under both in vitro and in vivo settings. Results: Combining MEM, IPM, and ETP with the corresponding βLIs restored the isolates’ susceptibilities to those antimicrobial agents in 66.7%, 57.1%, and 30.8% of the samples, respectively. Survival studies in mice revealed 100% survival rates when MEM was combined with either Avibactam or Relebactam against blaOXA-48 and blaKPC-2, respectively. RT-qPCR demonstrated the consistent overexpression of blaOXA-48 upon treatment, without hindering Avibactam’s activity, while blaNDM-1 and blaKPC-2 experienced variable expression levels upon treatment under in vitro and in vivo settings despite their effective phenotypic results. Conclusion: New carbapenem/βLI combinations may be viable alternatives to antimicrobial combination therapy as they displayed high efficacy in vitro and in vivo. Meropenem/Avibactam and Meropenem/Relebactam should be tested on larger sample sizes with different carbapenemases before progressing further in its preclinical development.
- 30 April 2019
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 10, 933
Open AccessEvaluating the Efficacies of Carbapenem/β-Lactamase Inhibitors Against Carbapenem-Resistant Gram-Negative Bacteria in vitro and in vivo
Background: Carbapenem-resistant Gram-negative bacteria are a major clinical concern as they cause virtually untreatable infections since carbapenems are among the last-resort antimicrobial agents. β-Lactamases implicated in carbapenem resistance include KPC, NDM, and OXA-type carbapenemases. Antimicrobial combination therapy is the current treatment approach against carbapenem resistance in order to limit the excessive use of colistin; however, its advantages over monotherapy remain debatable. An alternative treatment strategy would be the use of carbapenem/β-lactamase inhibitor (βLI) combinations. In this study, we assessed the in vitro and in vivo phenotypic and molecular efficacies of three βLIs when combined with different carbapenems against carbapenem-resistant Gram-negative clinical isolates. The chosen βLIs were (1) Avibactam, against OXA-type carbapenemases, (2) calcium-EDTA, against NDM-1, and (3) Relebactam, against KPC-2. Methods: Six Acinetobacter baumannii clinical isolates were screened for blaOXA-23-like, blaOXA-24/40, blaOXA-51-like, blaOXA-58, and blaOXA-143-like, and eight Enterobacteriaceae clinical isolates were screened for blaOXA-48, blaNDM-1, and blaKPC-2. The minimal inhibitory concentrations of Imipenem (IPM), Ertapenem (ETP), and Meropenem (MEM) with corresponding βLIs for each isolate were determined. The efficacy of the most suitable in vitro treatment option against each of blaOXA-48, blaNDM-1, and blaKPC-2 was assessed via survival studies in a BALB/c murine infection model. Finally, RT-qPCR was performed to assess the molecular response of the genes of resistance to the carbapenem/βLI combinations used under both in vitro and in vivo settings. Results: Combining MEM, IPM, and ETP with the corresponding βLIs restored the isolates’ susceptibilities to those antimicrobial agents in 66.7%, 57.1%, and 30.8% of the samples, respectively. Survival studies in mice revealed 100% survival rates when MEM was combined with either Avibactam or Relebactam against blaOXA-48 and blaKPC-2, respectively. RT-qPCR demonstrated the consistent overexpression of blaOXA-48 upon treatment, without hindering Avibactam’s activity, while blaNDM-1 and blaKPC-2 experienced variable expression levels upon treatment under in vitro and in vivo settings despite their effective phenotypic results. Conclusion: New carbapenem/βLI combinations may be viable alternatives to antimicrobial combination therapy as they displayed high efficacy in vitro and in vivo. Meropenem/Avibactam and Meropenem/Relebactam should be tested on larger sample sizes with different carbapenemases before progressing further in its preclinical development.
- Open Access
- 21 February 2018
- Published by Journal of Infection in Developing Countries in The Journal of Infection in Developing Countries
- Vol. 12 (02.1) , 4S
Increase of blaOXA-23-like in Acinetobacter baumannii at a tertiary care center in Lebanon between 2007 and 2013
Introduction: The multi-drug resistant nature of Acinetobacter baumannii isolates have rendered many broad-spectrum antimicrobial agents ineffective against them. The purpose of this retrospective study is to define and compare the molecular characteristics of A. baumannii isolates from patients at a tertiary care center in Lebanon from two outbreaks, the first in 2007-2008, as part of a case-controlled study involving A. baumannii cases admitted to the ICU, and the second in 2013. Methodology: A total of 148 A. baumannii clinical isolates were collected from various clinical specimens during 2007-2008 and 2013. All A. baumannii isolates were screened for blaOXA-23-like and blaOXA-51-like genes of carbapenem resistance. Additionally, in an effort to assess the degree of the isolates’ genomic relatedness, random amplification of polymorphic DNA (RAPD) was performed. Results: There was an increase in the prevalence of blaOXA-23-like and blaOXA-51-like genes between the two time periods; however, only 22% isolate genomic relatedness was calculated between 2007-2008 and 2013. Taking 80% as a margin of compatibility, 31 distinct clusters containing 2 to 11 strains were observed when both time periods were analyzed. Conclusion: The presence of numerous clusters accompanied by a predominant increase in the prevalence of blaOXA-23-like between 2007 and 2013 suggests a horizontal transmission of the gene within various strains of the species, contributing to the persistent increase in carbapenem resistance over the years. Therefore, infection control measures are required with compliance among all healthcare workers.
- 21 February 2018
- Published by Journal of Infection in Developing Countries in The Journal of Infection in Developing Countries
- Vol. 12 (02.1) , 4S
Open AccessIncrease of blaOXA-23-like in Acinetobacter baumannii at a tertiary care center in Lebanon between 2007 and 2013
Introduction: The multi-drug resistant nature of Acinetobacter baumannii isolates have rendered many broad-spectrum antimicrobial agents ineffective against them. The purpose of this retrospective study is to define and compare the molecular characteristics of A. baumannii isolates from patients at a tertiary care center in Lebanon from two outbreaks, the first in 2007-2008, as part of a case-controlled study involving A. baumannii cases admitted to the ICU, and the second in 2013. Methodology: A total of 148 A. baumannii clinical isolates were collected from various clinical specimens during 2007-2008 and 2013. All A. baumannii isolates were screened for blaOXA-23-like and blaOXA-51-like genes of carbapenem resistance. Additionally, in an effort to assess the degree of the isolates’ genomic relatedness, random amplification of polymorphic DNA (RAPD) was performed. Results: There was an increase in the prevalence of blaOXA-23-like and blaOXA-51-like genes between the two time periods; however, only 22% isolate genomic relatedness was calculated between 2007-2008 and 2013. Taking 80% as a margin of compatibility, 31 distinct clusters containing 2 to 11 strains were observed when both time periods were analyzed. Conclusion: The presence of numerous clusters accompanied by a predominant increase in the prevalence of blaOXA-23-like between 2007 and 2013 suggests a horizontal transmission of the gene within various strains of the species, contributing to the persistent increase in carbapenem resistance over the years. Therefore, infection control measures are required with compliance among all healthcare workers.